A citation-based method for searching scientific literature

Philip J Mease, Iain B McInnes, Lai-Shan Tam, Kiefer Eaton, Steve Peterson, Agata Schubert, Soumya D Chakravarty, Anna Parackal, Chetan S Karyekar, Sandhya Nair, Wolf-Henning Boehncke, Christopher Ritchlin. Rheumatology (Oxford) 2021
Times Cited: 19







List of co-cited articles
251 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update.
Laure Gossec, Xenofon Baraliakos, Andreas Kerschbaumer, Maarten de Wit, Iain McInnes, Maxime Dougados, Jette Primdahl, Dennis G McGonagle, Daniel Aletaha, Andra Balanescu,[...]. Ann Rheum Dis 2020
307
57

Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
Atul Deodhar, Philip S Helliwell, Wolf-Henning Boehncke, Alexa P Kollmeier, Elizabeth C Hsia, Ramanand A Subramanian, Xie L Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou,[...]. Lancet 2020
108
52

Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.
Philip J Mease, Proton Rahman, Alice B Gottlieb, Alexa P Kollmeier, Elizabeth C Hsia, Xie L Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou, Yanli Zhuang,[...]. Lancet 2020
106
47

Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis.
Adeline Ruyssen-Witrand, Richard Perry, Clare Watkins, George Braileanu, Gayathri Kumar, Sandeep Kiri, Debby Nott, Soyi Liu-Leage, Susanne Hartz, Christophe Sapin. RMD Open 2020
28
31

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.
Jasvinder A Singh, Gordon Guyatt, Alexis Ogdie, Dafna D Gladman, Chad Deal, Atul Deodhar, Maureen Dubreuil, Jonathan Dunham, M Elaine Husni, Sarah Kenny,[...]. Arthritis Rheumatol 2019
191
31

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis.
Laura C Coates, Arthur Kavanaugh, Philip J Mease, Enrique R Soriano, Maria Laura Acosta-Felquer, April W Armstrong, Wilson Bautista-Molano, Wolf-Henning Boehncke, Willemina Campbell, Alberto Cauli,[...]. Arthritis Rheumatol 2016
539
26

Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial.
Christopher T Ritchlin, Arthur Kavanaugh, Joseph F Merola, Georg Schett, Jose U Scher, Richard B Warren, Alice B Gottlieb, Deepak Assudani, Kathy Bedford-Rice, Jason Coarse,[...]. Lancet 2020
72
26

Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial.
Andrew Östör, Filip Van den Bosch, Kim Papp, Cecilia Asnal, Ricardo Blanco, Jacob Aelion, Gabriela Alperovich, Wenjing Lu, Zailong Wang, Ahmed M Soliman,[...]. Ann Rheum Dis 2022
17
29

Classification criteria for psoriatic arthritis: development of new criteria from a large international study.
William Taylor, Dafna Gladman, Philip Helliwell, Antonio Marchesoni, Philip Mease, Herman Mielants. Arthritis Rheum 2006
21


A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.
Philip J Mease, Josef S Smolen, Frank Behrens, Peter Nash, Soyi Liu Leage, Lingnan Li, Hasan Tahir, Melinda Gooderham, Eswar Krishnan, Hong Liu-Seifert,[...]. Ann Rheum Dis 2020
113
21

Psoriatic Arthritis.
Christopher T Ritchlin, Robert A Colbert, Dafna D Gladman. N Engl J Med 2017
613
21

Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis.
Iain B McInnes, Proton Rahman, Alice B Gottlieb, Elizabeth C Hsia, Alexa P Kollmeier, Soumya D Chakravarty, Xie L Xu, Ramanand A Subramanian, Prasheen Agarwal, Shihong Sheng,[...]. Arthritis Rheumatol 2021
18
22

Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
Dafna Gladman, William Rigby, Valderilio F Azevedo, Frank Behrens, Ricardo Blanco, Andrzej Kaszuba, Elizabeth Kudlacz, Cunshan Wang, Sujatha Menon, Thijs Hendrikx,[...]. N Engl J Med 2017
256
21

Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
Iain B McInnes, Frank Behrens, Philip J Mease, Arthur Kavanaugh, Christopher Ritchlin, Peter Nash, Jordi Gratacós Masmitja, Philippe Goupille, Tatiana Korotaeva, Alice B Gottlieb,[...]. Lancet 2020
91
21

Biological DMARD efficacy in psoriatic arthritis: a systematic literature review and meta-analysis on articular, enthesitis, dactylitis, skin and functional outcomes.
Numa Simons, Yannick Degboé, Thomas Barnetche, Alain Cantagrel, Adeline Ruyssen-Witrand, Arnaud Constantin. Clin Exp Rheumatol 2020
8
50

Effect of biologics on radiographic progression of peripheral joint in patients with psoriatic arthritis: meta-analysis.
Dongze Wu, Chen Li, Shuo Zhang, Priscilla Wong, Yihan Cao, James F Griffith, Xinlu Zhang, Jieruo Gu, Lai-Shan Tam. Rheumatology (Oxford) 2020
8
50


Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced.
Christopher T Ritchlin, Philip S Helliwell, Wolf-Henning Boehncke, Enrique R Soriano, Elizabeth C Hsia, Alexa P Kollmeier, Soumya D Chakravarty, Federico Zazzetti, Ramanand A Subramanian, Xie L Xu,[...]. RMD Open 2021
13
23

Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis.
Iain B McInnes, Proton Rahman, Alice B Gottlieb, Elizabeth C Hsia, Alexa P Kollmeier, Xie L Xu, Yusang Jiang, Shihong Sheng, May Shawi, Soumya D Chakravarty,[...]. Arthritis Rheumatol 2022
10
30



Psoriatic arthritis: state of the art review.
Laura C Coates, Philip S Helliwell. Clin Med (Lond) 2017
113
15

Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis.
Philip J Mease, Alice B Gottlieb, Désirée van der Heijde, Oliver FitzGerald, Alyssa Johnsen, Marleen Nys, Subhashis Banerjee, Dafna D Gladman. Ann Rheum Dis 2017
122
15

Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score.
Monika M Schoels, Daniel Aletaha, Farideh Alasti, Josef S Smolen. Ann Rheum Dis 2016
213
15

Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis.
Iain B McInnes, Jaclyn K Anderson, Marina Magrey, Joseph F Merola, Yi Liu, Mitsumasa Kishimoto, Slawomir Jeka, Cesar Pacheco-Tena, Xin Wang, Liang Chen,[...]. N Engl J Med 2021
54
15

Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial.
Xenofon Baraliakos, Laure Gossec, Effie Pournara, Slawomir Jeka, Antonio Mera-Varela, Salvatore D'Angelo, Barbara Schulz, Michael Rissler, Kriti Nagar, Chiara Perella,[...]. Ann Rheum Dis 2021
38
15

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.
Philip J Mease, Dafna D Gladman, Christopher T Ritchlin, Eric M Ruderman, Serge D Steinfeld, Ernest H S Choy, John T Sharp, Peter A Ory, Renee J Perdok, Mark A Weinberg. Arthritis Rheum 2005
686
15

Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression.
Philip J Mease, Alan J Kivitz, Francis X Burch, Evan L Siegel, Stanley B Cohen, Peter Ory, David Salonen, Joel Rubenstein, John T Sharp, Wayne Tsuji. Arthritis Rheum 2004
690
15

Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
Philip Mease, Stephen Hall, Oliver FitzGerald, Désirée van der Heijde, Joseph F Merola, Francisco Avila-Zapata, Dorota Cieślak, Daniela Graham, Cunshan Wang, Sujatha Menon,[...]. N Engl J Med 2017
272
15

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Philip J Mease, Désirée van der Heijde, Christopher T Ritchlin, Masato Okada, Raquel S Cuchacovich, Catherine L Shuler, Chen-Yen Lin, Daniel K Braun, Chin H Lee, Dafna D Gladman. Ann Rheum Dis 2017
315
15

Treatment guidelines in psoriatic arthritis.
Alexis Ogdie, Laura C Coates, Dafna D Gladman. Rheumatology (Oxford) 2020
57
15


Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.
Philip Mease, Désirée van der Heijde, Robert Landewé, Shephard Mpofu, Proton Rahman, Hasan Tahir, Atul Singhal, Elke Boettcher, Sandra Navarra, Karin Meiser,[...]. Ann Rheum Dis 2018
149
15

Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial.
Lars Erik Kristensen, Mauro Keiserman, Kim Papp, Leslie McCasland, Douglas White, Wenjing Lu, Zailong Wang, Ahmed M Soliman, Ann Eldred, Lisa Barcomb,[...]. Ann Rheum Dis 2022
19
15

Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study.
Philip J Mease, Saima Chohan, Ferran J Garcia Fructuoso, Michael E Luggen, Proton Rahman, Siba P Raychaudhuri, Richard C Chou, Alan M Mendelsohn, Stephen J Rozzo, Alice Gottlieb. Ann Rheum Dis 2021
12
25

Dermatologists' Role in the Early Diagnosis of Psoriatic Arthritis: Expert Recommendations.
I Belinchón, L Salgado-Boquete, A López-Ferrer, M Ferran, P Coto-Segura, R Rivera, D Vidal, L Rodríguez, P de la Cueva, R Queiro. Actas Dermosifiliogr (Engl Ed) 2020
7
42

A Systematic Review With Network Meta-Analysis of the Available Biologic Therapies for Psoriatic Disease Domains.
Tiago Torres, Anabela Barcelos, Paulo Filipe, João Eurico Fonseca. Front Med (Lausanne) 2021
6
50

'Too much of a good thing': can network meta-analysis guide treatment decision-making in psoriatic arthritis?
Helena Marzo-Ortega, Jon Packham, Mar Pujades-Rodriguez. Rheumatology (Oxford) 2021
3
100

Real-life efficacy of guselkumab in patients with early psoriatic arthritis.
Ilenia Pantano, Daniele Mauro, Francesca Romano, Alessio Gambardella, Mario Valenti, Davide Simone, Daniela Iacono, Antonio Costanzo, Giuseppe Argenziano, Francesco Ciccia. Rheumatology (Oxford) 2022
6
50

Disease Characteristics and the Burden of Joint and Skin Involvement Amongst People With Psoriatic Arthritis: A Population Survey.
William Tillett, Joseph F Merola, Diamant Thaçi, Elizabeth Holdsworth, Nicola Booth, L Steve Lobosco, Gary Milligan, Matthew M Hufford, Julie A Birt, Wolf-Henning Boehncke. Rheumatol Ther 2020
10
20

The epidemiology of psoriatic arthritis: A literature review.
Paras Karmacharya, Rikesh Chakradhar, Alexis Ogdie. Best Pract Res Clin Rheumatol 2021
14
14

Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults.
Wolf-Henning Boehncke, Nicolo Costantino Brembilla, Michael John Nissen. Expert Rev Clin Immunol 2021
14
14

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Peter Nash, Bruce Kirkham, Masato Okada, Proton Rahman, Benard Combe, Gerd-Ruediger Burmester, David H Adams, Lisa Kerr, Chin Lee, Catherine L Shuler,[...]. Lancet 2017
224
10


Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis.
Vinod Chandran, Sita Bhella, Catherine Schentag, Dafna D Gladman. Ann Rheum Dis 2007
120
10


Psoriatic arthritis: epidemiology, clinical features, course, and outcome.
D D Gladman, C Antoni, P Mease, D O Clegg, P Nash. Ann Rheum Dis 2005
912
10

Ultrasonographic and Clinical Assessment of Peripheral Enthesitis in Patients with Psoriatic Arthritis, Psoriasis, and Fibromyalgia Syndrome: The ULISSE Study.
Pierluigi Macchioni, Carlo Salvarani, Niccolò Possemato, Marwin Gutierrez, Walter Grassi, Stefania Gasparini, Carlo Perricone, Fabio Massimo Perrotta, Rosa Daniela Grembiale, Caterina Bruno,[...]. J Rheumatol 2019
41
10



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.